The study conducted by the team revealed that the inhibition of BRG1 significantly impeded the proliferation and survival of anaplastic large-cell lymphoma cells, suggesting that BRG1 could serve as a viable target for anaplastic large-cell lymphoma treatment. The gene discussed is SMARCA4; the disease is anaplastic large cell lymphoma.